Funding awarded
- Phase 2 study of Tovorafenib (Day 101) in Relapsed and Refractory Langerhans Cell Histiocytosis awarded by Medical College of Virginia Foundation Principal Investigator 2025 - 2027
- Biomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signatures awarded by Hyundai Hope on Wheels Foundation Principal Investigator 2024 - 2026
- Clinical and Translational Science Center- Institutional CTSC Internal Funding UL1 awarded by CTSC Cost Share Co-Principal Investigator 2022 - 2027